Notice: This company has been marked as potentially delisted and may not be actively trading. Taro Pharmaceutical Industries (TARO) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestTrends Get the Latest News and Ratings for TARO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Taro Pharmaceutical Industries and its competitors. Enter your email to sign up for newsletter Sign Up TARO Analyst Ratings Over TimeTypeCurrent Forecast11/16/23 to 11/15/241 Month Ago10/17/23 to 10/16/243 Months Ago8/18/23 to 8/17/241 Year Ago11/16/22 to 11/16/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)1 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$43.00$43.00$43.00$35.00Forecasted Upside0.07% Upside0.07% Upside0.07% Upside-1.91% DownsideConsensus RatingHoldHoldHoldBuy Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide TARO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History TARO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Taro Pharmaceutical Industries Stock vs. The CompetitionTypeTaro Pharmaceutical IndustriesMedical CompaniesS&P 500Consensus Rating Score 2.00 2.80 2.50Consensus RatingHoldModerate BuyModerate BuyPredicted Upside0.07% Upside26,221.50% Upside8.88% UpsideNews Sentiment RatingNegative NewsSee Recent TARO NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails1/18/2024HC Wainwright2 of 5 starsR. SelvarajuSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$43.00+4.17%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:59 AM ET. TARO Forecast - Frequently Asked Questions What is Taro Pharmaceutical Industries' forecast for 2025? According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Taro Pharmaceutical Industries is $43.00, with a high forecast of $43.00 and a low forecast of $43.00. Should I buy or sell Taro Pharmaceutical Industries stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last twelve months. There is currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TARO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TARO, but not buy additional shares or sell existing shares. Does Taro Pharmaceutical Industries's stock price have much upside? According to analysts, Taro Pharmaceutical Industries's stock has a predicted upside of 0.07% based on their 12-month stock forecasts. Do Wall Street analysts like Taro Pharmaceutical Industries more than its competitors? Analysts like Taro Pharmaceutical Industries less than other "medical" companies. The consensus rating for Taro Pharmaceutical Industries is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TARO compares to other companies. Stock Forecasts and Research Tools Related Companies Grifols Stock Forecast Elanco Animal Health Stock Forecast Blueprint Medicines Stock Forecast Cytokinetics Stock Forecast Nuvalent Stock Forecast Ionis Pharmaceuticals Stock Forecast Corcept Therapeutics Stock Forecast Avidity Biosciences Stock Forecast Biohaven Stock Forecast Ultragenyx Pharmaceutical Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide This page (NYSE:TARO) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taro Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taro Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
